Markers of platelet activation and apoptosis during storage of apheresis- and buffy coat-derived platelet concentrates for 7 days

Transfusion

Volumn 49, Issue 1, 2009, Pages 108-117

  Albanyan, Abdul Majeed ^a   Harrison, Paul ^b   Murphy, Michael F ^b  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD47 ANTIGEN; CD61 ANTIGEN; GLYCOPROTEIN IB ALPHA; PADGEM PROTEIN; PHOSPHATIDYLSERINE; THROMBOCYTE CONCENTRATE;

APHERESIS; APOPTOSIS; ARTICLE; BUFFY COAT METHOD; CELL VIABILITY; INTERMETHOD COMPARISON; ISOLATION PROCEDURE; MITOCHONDRIAL MEMBRANE POTENTIAL; PROTEIN EXPRESSION; QUALITY CONTROL; STAINING; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTE PRESERVATION;

ANTIGENS, CD; APOPTOSIS; BLOOD PLATELETS; CELL SURVIVAL; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; PLATELET ACTIVATION; PLATELETPHERESIS; PRESERVATION, BIOLOGICAL; TIME FACTORS;

EID: 58149129396     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2008.01942.x     Document Type: Article

References (35)

1. Murphy S, Heaton WA, Rebulla P. Platelet production in the Old World - and the New. Transfusion 1996 36 : 751 4.
2. Murphy S. Platelets from pooled buffy coats: an update. Transfusion 2005 45 : 634 9.
3. Sullivan MT, Wallace EL. Blood collection and transfusion in the United States in 1999. Transfusion 2005 45 : 141 8.
4. Vassallo RR, Murphy S. A critical comparison of platelet preparation methods. Curr Opin Hematol 2006 13 : 323 30.
5. Chambers LA, Herman JH. Considerations in the selection of a platelet component: apheresis versus whole blood-derived. Transfus Med Rev 1999 13 : 311 22.
6. Heal JM, Blumberg N. Optimizing platelet transfusion therapy. Blood Rev 2004 18 : 149 65.
7. Heddle NM, Blajchman MA, Meyer RM, Lipton JH, Walker IR, Sher GD, Constantini LA, Patterson B, Roberts RS, Thorpe KE, Levine MN. A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion 2002 42 : 556 66.
8. Arnold DM, Heddle NM, Kulczycky M, Carruthers J, Sigouin C, Blajchman MA. In vivo recovery and survival of apheresis and whole blood-derived platelets: a paired comparison in healthy volunteers. Transfusion 2006 46 : 257 64.
9. Heddle NM, Arnold DM, Boye D, Webert KE, Resz I, Dumont LJ. Comparing the efficacy and safety of apheresis and whole blood-derived platelet transfusions: a systematic review. Transfusion 2008 48 : 1447 58.
10. Sloand EM, Yu M, Klein HG. Comparison of random-donor platelet concentrates prepared from whole blood units and platelets prepared from single-donor apheresis collections. Transfusion 1996 36 : 955 9.
11. Metcalfe P, Williamson LM, Reutelingsperger CP, Swann I, Ouwehand WH, Goodall AH. Activation during preparation of therapeutic platelets affects deterioration during storage: a comparative flow cytometric study of different production methods. Br J Haematol 1997 98 : 86 95.
12. Krailadsiri P, Seghatchian J. Are all leucodepleted platelet concentrates equivalent? Comparison of Cobe LRS Turbo, Haemonetics MCS+ LD, and filtered pooled buffy-coat-derived platelets. Vox Sang 2000 78 : 171 5.
13. Bock M, Rahrig S, Kunz D, Lutze G, Heim MU. Platelet concentrates derived from buffy coat and apheresis: biochemical and functional differences. Transfus Med 2002 12 : 317 24.
14. Hagberg IA, Akkok CA, Lyberg T, Kjeldsen-Kragh J. Apheresis-induced platelet activation: comparison of three types of cell separators. Transfusion 2000 40 : 182 92.
15. Harrison P. Platelet function analysis. Blood Rev 2005 19 : 111 23.
16. UK Blood Transfusion Services. Guidelines for the blood transfusion services in the United Kingdom. 7th ed. London : The Stationery Office 2005.
17. Guppy M, Abas L, Arthur PG, Whisson ME. The Pasteur effect in human platelets: implications for storage and metabolic control. Br J Haematol 1995 91 : 752 7.
18. Li J, Lockerbie O, de Korte D, Rice J, McLean R, Goodrich RP. Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology. Transfusion 2005 45 : 920 6.
19. Hartley PS, Savill J, Brown SB. The death of human platelets during incubation in citrated plasma involves shedding of CD42b and aggregation of dead platelets. Thromb Haemost 2006 95 : 100 6.
20. Perrotta PL, Perrotta CL, Snyder EL. Apoptotic activity in stored human platelets. Transfusion 2003 43 : 526 35.
21. Li J, de Korte D, Woolum MD, Ruane PH, Keil SD, Lockerbie O, McLean R, Goodrich RP. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products. Vox Sang 2004 87 : 82 90.
22. Verhoeven AJ, Verhaar R, Gouwerok EG, de Korte D. The mitochondrial membrane potential in human platelets: a sensitive parameter for platelet quality. Transfusion 2005 45 : 82 9.
23. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med 2000 6 : 513 9.
24. Zamzami N, Kroemer G. Apoptosis: mitochondrial membrane permeabilization - the (w)hole story? Curr Biol 2003 13 : R71 3.
25. Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S, Kelly PN, Ekert PG, Metcalf D, Roberts AW, Huang DC, Kile BT. Programmed anuclear cell death delimits platelet life span. Cell 2007 128 : 1173 86.
26. Dumont LJ, VandenBroeke T. Seven-day storage of apheresis platelets: report of an in vitro study. Transfusion 2003 43 : 143 50.
27. Bertino AM, Qi XQ, Li J, Xia Y, Kuter DJ. Apoptotic markers are increased in platelets stored at 37 degrees C. Transfusion 2003 43 : 857 66.
28. Holme S, Heaton A. In vitro platelet ageing at 22 degrees C is reduced compared to in vivo ageing at 37 degrees C. Br J Haematol 1995 91 : 212 8.
29. Rock G, Figueredo A. Metabolic changes during platelet storage. Transfusion 1976 16 : 571 9.
30. Wu Y, Tibrewal N, Birge RB. Phosphatidylserine recognition by phagocytes: a view to a kill. Trends Cell Biol 2006 16 : 189 97.
31. Heemskerk JW, Comfurius P, Feijge MA, Bevers EM. Measurement of the platelet procoagulant response. Methods Mol Biol 2004 272 : 135 44.
32. Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP. Role of CD47 as a marker of self on red blood cells. Science 2000 288 : 2051 4.
33. Olsson M, Bruhns P, Frazier WA, Ravetch JV, Oldenborg PA. Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia. Blood 2005 105 : 3577 82.
34. Olsson M, Nilsson A, Oldenborg PA. Target cell CD47 regulates macrophage activation and erythrophagocytosis. Transfus Clin Biol 2006 13 : 39 43.
35. Harrison P, Robinson M, Mackie I, Machin S. Reticulated platelets. Platelets 1997 8 : 379 83.